Comparing Tevogen Bio (TVGN) and Its Peers

Tevogen Bio (NASDAQ:TVGN) is one of 618 publicly-traded companies in the “MED – BIOMED/GENE” industry, but how does it compare to its rivals? We will compare Tevogen Bio to similar companies based on the strength of its risk, dividends, analyst recommendations, earnings, profitability, institutional ownership and valuation.

Analyst Ratings

This is a summary of current recommendations and price targets for Tevogen Bio and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1	0	1	0	2.00
Tevogen Bio Competitors	5363	11952	37240	1121	2.61

Tevogen Bio currently has a consensus price target of $10.00, suggesting a potential upside of 2,031.29%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 66.49%. Given Tevogen Bio’s higher possible upside, equities research analysts plainly believe Tevogen Bio is more favorable than its rivals.

Volatility & Risk

Tevogen Bio has a beta of -0.86, meaning that its stock price is 186% less volatile than the S&P 500. Comparatively, Tevogen Bio’s rivals have a beta of 0.97, meaning that their average stock price is 3% less volatile than the S&P 500.

Institutional & Insider Ownership

51.1% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 73.2% of Tevogen Bio shares are owned by insiders. Comparatively, 13.7% of shares of all “MED – BIOMED/GENE” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Tevogen Bio and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-775.49%
Tevogen Bio Competitors	-1,441.95%	-644.91%	-28.37%

Valuation and Earnings

This table compares Tevogen Bio and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Tevogen Bio	N/A	-$13.73 million	-2.47
Tevogen Bio Competitors	$953.09 million	-$45.98 million	14.21

Tevogen Bio’s rivals have higher revenue, but lower earnings than Tevogen Bio. Tevogen Bio is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Tevogen Bio rivals beat Tevogen Bio on 8 of the 13 factors compared.

About Tevogen Bio

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.